Economist Who Predicted Covid Tyranny Warns of Imminent Collapse
________
Source: The Defender
Moderna Wednesday announced it will soon request Emergency Use Authorization for its pediatric COVID vaccine. The company said the majority of COVID cases observed during its pediatric clinical trials were mild, making it impossible to detect the vaccine's protective effect against the worst outcomes.
By Megan Redshaw | March 23, 2022
Moderna also said the vaccine, when administered at a smaller dose, produced an immune response in the younger age group similar to the response produced by its vaccine authorized for adolescents and young adults, ages 12 to 17.
Yet, data show the vaccine may not be effective at reducing severe COVID in children, who make up only a small percentage of SARS-CoV-2 infections — most of which are asymptomatic and mild.
Moderna released partial results from its two pediatric clinical trials in 6,900 children showing the mRNA shots were only about 44% effective at preventing symptomatic infection in children 6 months to 2 years old, and only 37% effective in children aged 2 to 5.
However, Moderna said its pediatric trials were designed to study safety and the immune response, not effectiveness.
"We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age,” Stéphane Bancel, CEO of Moderna, said in a statement.
"We now have clinical data on the performance of our vaccine from infants six months of age through older adults. Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible. "Moderna's pediatric clinical trials were conducted using two 25-microgram doses each — a fourth of the adult dose — and during a time period when the Omicron variant was the predominant strain.
Moderna said the safety profile of two pediatric doses was generally “consistent with that observed in children age 6 to under 12, in adolescents age 12 to 17 and in adults."
Adverse events were mild or moderate and were more frequently reported after the second dose. No cases of myocarditis — a potentially fatal type of heart inflammation linked to mRNA vaccines — were reported, the company said.
Moderna did not report any details on types of side effects except for data on children who experienced fevers. The company said about 15% of children had fevers higher than 100.4 degrees, and 1 in 500 experienced a fever higher than 104 degrees.
Moderna did not disclose whether children required hospitalization as a result of the fevers or other side effects.
The company said the majority of COVID cases observed were mild and no severe disease, hospitalizations or deaths were reported among any of the children who participated in the trial, making it impossible to detect the vaccine's protective effect against the worst outcomes.
"The absence of any severe disease, hospitalization or death in the study precludes the assessment of vaccine efficacy against these endpoints," the company said.
Yet, Moderna said its efficacy results were statistically significant, and lower efficacy against COVID-19 infection due to Omicron was anticipated based on how the vaccine performs in adults.
According to The Washington Post, the company said its statistical analysis showed vaccine efficacy was "above zero."
"We're optimistic that we can bring the vaccine forward, hopefully reasonably quickly," Jacqueline Miller, Moderna's senior vice president of infectious diseases, told the Post.
Miller said the company plans to test a booster dose in children and is submitting a proposal to regulators to test a third vaccine dose to be administered four months after children complete their initial series of two shots.
Please go to The Defender to read more.
The vaccinated no longer have control over their own cognizance:
Source: The Defender
Moderna Wednesday announced it will soon request Emergency Use Authorization for its pediatric COVID vaccine. The company said the majority of COVID cases observed during its pediatric clinical trials were mild, making it impossible to detect the vaccine's protective effect against the worst outcomes.
By Megan Redshaw | March 23, 2022
Moderna today announced plans to request Emergency Use Authorization (EUA) for its pediatric COVID-19 vaccine, citing preliminary data showing the two-dose regimen was safe for children under age 6, including toddlers and infants.
Moderna also said the vaccine, when administered at a smaller dose, produced an immune response in the younger age group similar to the response produced by its vaccine authorized for adolescents and young adults, ages 12 to 17.
Yet, data show the vaccine may not be effective at reducing severe COVID in children, who make up only a small percentage of SARS-CoV-2 infections — most of which are asymptomatic and mild.
Moderna released partial results from its two pediatric clinical trials in 6,900 children showing the mRNA shots were only about 44% effective at preventing symptomatic infection in children 6 months to 2 years old, and only 37% effective in children aged 2 to 5.
However, Moderna said its pediatric trials were designed to study safety and the immune response, not effectiveness.
"We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age,” Stéphane Bancel, CEO of Moderna, said in a statement.
"We now have clinical data on the performance of our vaccine from infants six months of age through older adults. Given the need for a vaccine against COVID-19 in infants and young children, we are working with the U.S. FDA and regulators globally to submit these data as soon as possible. "Moderna's pediatric clinical trials were conducted using two 25-microgram doses each — a fourth of the adult dose — and during a time period when the Omicron variant was the predominant strain.
Moderna said the safety profile of two pediatric doses was generally “consistent with that observed in children age 6 to under 12, in adolescents age 12 to 17 and in adults."
Adverse events were mild or moderate and were more frequently reported after the second dose. No cases of myocarditis — a potentially fatal type of heart inflammation linked to mRNA vaccines — were reported, the company said.
Moderna did not report any details on types of side effects except for data on children who experienced fevers. The company said about 15% of children had fevers higher than 100.4 degrees, and 1 in 500 experienced a fever higher than 104 degrees.
Moderna did not disclose whether children required hospitalization as a result of the fevers or other side effects.
The company said the majority of COVID cases observed were mild and no severe disease, hospitalizations or deaths were reported among any of the children who participated in the trial, making it impossible to detect the vaccine's protective effect against the worst outcomes.
"The absence of any severe disease, hospitalization or death in the study precludes the assessment of vaccine efficacy against these endpoints," the company said.
Yet, Moderna said its efficacy results were statistically significant, and lower efficacy against COVID-19 infection due to Omicron was anticipated based on how the vaccine performs in adults.
According to The Washington Post, the company said its statistical analysis showed vaccine efficacy was "above zero."
"We're optimistic that we can bring the vaccine forward, hopefully reasonably quickly," Jacqueline Miller, Moderna's senior vice president of infectious diseases, told the Post.
Miller said the company plans to test a booster dose in children and is submitting a proposal to regulators to test a third vaccine dose to be administered four months after children complete their initial series of two shots.
Please go to The Defender to read more.
________
Related material on the technocracy and digital medical tyranny:
Injections and patents (weaponized patents):
More:
Comply and you die:
Rudolf Steiner on vaccinations shutting down the species' spiritual connections and growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.